Evidence map›Paper›PMID 33356393›Full record

ArticleArteriosclerosis, thrombosis, and vascular biology2021

CROT (Carnitine O-Octanoyltransferase) Is a Novel Contributing Factor in Vascular Calcification via Promoting Fatty Acid Metabolism and Mitochondrial Dysfunction.

Takehito Okui, Masaya Iwashita, Maximillian A Rogers, Arda Halu, Samantha K Atkins, Shiori Kuraoka, Ilyes Abdelhamid, Hideyuki Higashi, Ashisha Ramsaroop, Masanori Aikawa and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Arteriosclerosis, thrombosis, and vascular biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Hypotaurine Reduces Glucose-Mediated Vascular Calcification.Acta physiologica (Oxford, England) · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Insights Into the Role of Mitochondria in Vascular Calcification.Frontiers in cardiovascular medicine · 2022
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 2 countries.

Takehito Okui *Center for Interdisciplinary Cardiovascular Sciences, Division of Cardiovascular Medicine (T.O., M.I., M.A.R., A.H., S.K.A., S.K., I.A., H.H., A.R., M.A., S.A.S., E.A.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Masaya Iwashita *Center for Interdisciplinary Cardiovascular Sciences, Division of Cardiovascular Medicine (T.O., M.I., M.A.R., A.H., S.K.A., S.K., I.A., H.H., A.R., M.A., S.A.S., E.A.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Maximillian A Rogers *Center for Interdisciplinary Cardiovascular Sciences, Division of Cardiovascular Medicine (T.O., M.I., M.A.R., A.H., S.K.A., S.K., I.A., H.H., A.R., M.A., S.A.S., E.A.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Arda HaluCenter for Interdisciplinary Cardiovascular Sciences, Division of Cardiovascular Medicine (T.O., M.I., M.A.R., A.H., S.K.A., S.K., I.A., H.H., A.R., M.A., S.A.S., E.A.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Samantha K AtkinsCenter for Interdisciplinary Cardiovascular Sciences, Division of Cardiovascular Medicine (T.O., M.I., M.A.R., A.H., S.K.A., S.K., I.A., H.H., A.R., M.A., S.A.S., E.A.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Shiori KuraokaCenter for Interdisciplinary Cardiovascular Sciences, Division of Cardiovascular Medicine (T.O., M.I., M.A.R., A.H., S.K.A., S.K., I.A., H.H., A.R., M.A., S.A.S., E.A.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Ilyes AbdelhamidCenter for Interdisciplinary Cardiovascular Sciences, Division of Cardiovascular Medicine (T.O., M.I., M.A.R., A.H., S.K.A., S.K., I.A., H.H., A.R., M.A., S.A.S., E.A.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Hideyuki HigashiCenter for Interdisciplinary Cardiovascular Sciences, Division of Cardiovascular Medicine (T.O., M.I., M.A.R., A.H., S.K.A., S.K., I.A., H.H., A.R., M.A., S.A.S., E.A.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Ashisha RamsaroopCenter for Interdisciplinary Cardiovascular Sciences, Division of Cardiovascular Medicine (T.O., M.I., M.A.R., A.H., S.K.A., S.K., I.A., H.H., A.R., M.A., S.A.S., E.A.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Masanori AikawaCenter for Interdisciplinary Cardiovascular Sciences, Division of Cardiovascular Medicine (T.O., M.I., M.A.R., A.H., S.K.A., S.K., I.A., H.H., A.R., M.A., S.A.S., E.A.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Sasha A SinghCenter for Interdisciplinary Cardiovascular Sciences, Division of Cardiovascular Medicine (T.O., M.I., M.A.R., A.H., S.K.A., S.K., I.A., H.H., A.R., M.A., S.A.S., E.A.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Elena AikawaCenter for Interdisciplinary Cardiovascular Sciences, Division of Cardiovascular Medicine (T.O., M.I., M.A.R., A.H., S.K.A., S.K., I.A., H.H., A.R., M.A., S.A.S., E.A.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Brigham and Women's Hospital · US

Funding

Improving Mitral Compensation In Ischemic RegurgitationR01HL141917 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI AIKAWA, ELENA, BISCHOFF, JOYCE E. · 2018 to 2021
$5.6M
Macrophage-derived microcalcificaitonsR01HL136431 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI AIKAWA, ELENA · 2017 to 2020
$2.7M
New driver of fibrosis and calcification in CAVDR01HL147095 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI AIKAWA, ELENA · 2019 to 2022
$2.4M
NHLBI NIH HHS R01 HL136431NHLBI NIH HHS R01 HL141917NHLBI NIH HHS R01 HL147095
6 · The paper itself

Abstract

objectiveVascular calcification is a critical pathology associated with increased cardiovascular event risk, but there are no Food and Drug Administration-approved anticalcific therapies. We hypothesized and validated that an unbiased screening approach would identify novel mediators of human vascular calcification. Approach and Results: We performed an unbiased quantitative proteomics and pathway network analysis that identified increased CROT (carnitine O-octanoyltransferase) in calcifying primary human coronary artery smooth muscle cells (SMCs). Additionally, human carotid artery atherosclerotic plaques contained increased immunoreactive CROT near calcified regions.

conclusionsCROT is a novel contributing factor in vascular calcification via promoting fatty acid metabolism and mitochondrial dysfunction, as such CROT inhibition has strong potential as an antifibrocalcific therapy.

Indexed as

Energy MetabolismAdultAnimalsAtherosclerosisCarnitine AcyltransferasesCells, CulturedDisease Models, AnimalFatty AcidsFemaleFibrosisHumansMaleMiceMice, Inbred C57BLMice, KnockoutMiddle AgedCarnitine Acyltransferasescarnitine octanoyltransferaseFatty AcidsProteomeReceptors, LDLcholesterollipidomicsmitochondriamuscle cellsproteomics

Identifiers

PMID33356393
PMCPMC8105275
OpenAlexW3115320043

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.